FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4254937951> ?p ?o ?g. }

• W4254937951 abstract "Background Aim of this research is to assess the efficacy and safety of tocilizumab (TCZ) in combination with methotrexate (MTX) in Indonesian patients with moderate to severe active rheumatoid arthritis (RA) who have an inadequate response to non-biologic DMARDs.Methods This was a interventional, prospective, single arm, multicenter, study in  Indonesian male or female patients aged ≥ 18 years old, with a diagnosis of RA for > 6 months based on ACR 1987 revised criteria with moderate to severe disease activity (DAS28 score > 3.2) after ≥ 12 weeks of non-biologic DMARDs treatment. The treatment consisted of tocilizumab, 8 mg/kg, intravenous (IV), every 4 weeks for a total of 6 infusion in combination with oral MTX (10−25 mg) every week. Efficacy was assessed based on the percentage of patients achieving low disease activity state (DAS28 < 3.2), percentage of patients achieving reduction > 1.2 point of DAS28, percentage of patients achieving remission (DAS28 < 2.6), and percentage of patients with ACR20, ACR50, and ACR70 responses. Descriptive statistics will be used for presentation of results.Results 100% patients reached low disease activity (DAS28 ≤ 3.2) at last study visit (week 24) and clinically significant improvement (reduction at least 1.2 units) at every visit in DAS28, both for ITT or PP patients. Remission (DAS28 < 2.6) was observed in 82.1% (ITT patients) and 93.1 % (PP patients) on last study visit. ACR20, ACR50, and ACR70 were achieved in 20%, 34%, and 34% (ITT patients), and 7%, 24%, and 62% (PP patients) on week 24. There were 3 out of 39 patients (7.69%) with adverse events (AE) and serious adverse events (SAE) that resulted in discontinuation of TCZ treatment, consisting of 1 patient with SAE of sepsis ec acquired community pneumonia, 1 patient with SAE of pneumonia tuberculosis, and 1 patient with AE of candidiasis. Most common adverse events were hepatic dysfunction (30.7%), hypercholesterolemia (23.1%), followed by arthralgia (20.5%) Twelve percent of patients needed dose modification due to elevated liver enzyme (elevated ALT/SGPT level).Conclusion Tocilizumab seems to be efficacious and likely to have good safety profile in non- biologic DMARD nonresponsive RA patients of PICTURE INA study.   Keywords: Rheumatoid Arthritis, Tocilizumab, DMARD, DAS28" @default.
• W4254937951 created "2022-05-12" @default.
• W4254937951 creator A5020213914 @default.
• W4254937951 creator A5036472374 @default.
• W4254937951 creator A5037090976 @default.
• W4254937951 creator A5040606583 @default.
• W4254937951 creator A5055309205 @default.
• W4254937951 creator A5070024802 @default.
• W4254937951 date "2018-08-07" @default.
• W4254937951 modified "2023-09-30" @default.
• W4254937951 title "The Use of Tocilizumab in Combination with Methotrexate in Indonesian Rheumatoid Arthritis Patients (PICTURE INA Study)" @default.
• W4254937951 doi "https://doi.org/10.32539/ijr.v10i1.91" @default.
• W4254937951 hasPublicationYear "2018" @default.
• W4254937951 type Work @default.
• W4254937951 citedByCount "0" @default.
• W4254937951 crossrefType "journal-article" @default.
• W4254937951 hasAuthorship W4254937951A5020213914 @default.
• W4254937951 hasAuthorship W4254937951A5036472374 @default.
• W4254937951 hasAuthorship W4254937951A5037090976 @default.
• W4254937951 hasAuthorship W4254937951A5040606583 @default.
• W4254937951 hasAuthorship W4254937951A5055309205 @default.
• W4254937951 hasAuthorship W4254937951A5070024802 @default.
• W4254937951 hasBestOaLocation W42549379511 @default.
• W4254937951 hasConcept C126322002 @default.
• W4254937951 hasConcept C203092338 @default.
• W4254937951 hasConcept C2776999253 @default.
• W4254937951 hasConcept C2777178219 @default.
• W4254937951 hasConcept C2777575956 @default.
• W4254937951 hasConcept C2781059491 @default.
• W4254937951 hasConcept C2908564923 @default.
• W4254937951 hasConcept C2909063479 @default.
• W4254937951 hasConcept C535046627 @default.
• W4254937951 hasConcept C71924100 @default.
• W4254937951 hasConcept C90924648 @default.
• W4254937951 hasConceptScore W4254937951C126322002 @default.
• W4254937951 hasConceptScore W4254937951C203092338 @default.
• W4254937951 hasConceptScore W4254937951C2776999253 @default.
• W4254937951 hasConceptScore W4254937951C2777178219 @default.
• W4254937951 hasConceptScore W4254937951C2777575956 @default.
• W4254937951 hasConceptScore W4254937951C2781059491 @default.
• W4254937951 hasConceptScore W4254937951C2908564923 @default.
• W4254937951 hasConceptScore W4254937951C2909063479 @default.
• W4254937951 hasConceptScore W4254937951C535046627 @default.
• W4254937951 hasConceptScore W4254937951C71924100 @default.
• W4254937951 hasConceptScore W4254937951C90924648 @default.
• W4254937951 hasIssue "1" @default.
• W4254937951 hasLocation W42549379511 @default.
• W4254937951 hasOpenAccess W4254937951 @default.
• W4254937951 hasPrimaryLocation W42549379511 @default.
• W4254937951 hasRelatedWork W189077404 @default.
• W4254937951 hasRelatedWork W1987294331 @default.
• W4254937951 hasRelatedWork W2098703756 @default.
• W4254937951 hasRelatedWork W21180250 @default.
• W4254937951 hasRelatedWork W2794029630 @default.
• W4254937951 hasRelatedWork W2948566177 @default.
• W4254937951 hasRelatedWork W2980857560 @default.
• W4254937951 hasRelatedWork W2996380604 @default.
• W4254937951 hasRelatedWork W3047477161 @default.
• W4254937951 hasRelatedWork W4252254106 @default.
• W4254937951 hasVolume "10" @default.
• W4254937951 isParatext "false" @default.
• W4254937951 isRetracted "false" @default.
• W4254937951 workType "article" @default.